U.S. Markets closed

Omeros price target raised to $28 from $18 at Wedbush

Wedbush raised Omeros' price target to $28 from $18 following a conversation with a high-volume cataract surgeon on OMS302's potential use and the changing regulatory environment. The analyst believes increased costs for topical solutions and pressure from the FDA could result in increased use of OMS302 after expected FDA approval in the U.S. The firm rates shares an Outperform.